multiple sclerosis

News

FDA slaps partial hold on Biogen, InnoCare MS drug

Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year f

Views & Analysis

Unlocking disease treatment with large-scale research

Ben Hargreaves examines why a research project in the UK could provide key insights to develop treatments against many of the most prominent diseases impacting society.

News

EU says Teva blocked generics to MS drug Copaxone

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it

News

Supreme court throws Novartis a lifeline for Gilenya defense

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.

News

Whistleblower gets $250m as Biogen settles US kickbacks case

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

News